After Biotech’s $43B Year, Growth Starts To Taper As Markets Mature

This article was taken from BisNow.com.

The spigot of venture capital funding and investments pouring into life sciences and biotech, which have supercharged the sector and the development of lab space, hit record levels last year — but experts expect the growth to slow down this year amid the broader dip in the markets.

The life sciences boom has always been connected to the IPO boom and stock market, according to Jay Chok, an associate professor at the Riggs School of Applied Life Science, who wrote his thesis on biotech IPOs. When the market and funding trends down, and the financing window closes for firms to go public, companies start being more frugal with their expenses to extend their burn rate. That eventually impacts real estate.

Read the full article